Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 1/20 | 0.64 |
| ▸ | NT5E | P21589 | 1/20 | 0.63 |
| ▸ | HINT1 | P49773 | 6/20 | 0.61 |
| ▸ | TGM2 | P21980 | 1/20 | 0.59 |
| ▸ | GSK3A | P49840 | 2/20 | 0.57 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.57 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | PNP | P00491 | 1/20 | 0.55 |
| ▸ | KRAS | P01116 | 6/20 | 0.53 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16113889 | 1.00 | AHCY (0.64) | AHCYNT5EHINT1TGM2GSK3A | |
| SCHEMBL13833306 | 1.00 | AHCY (0.64) | AHCYNT5EHINT1TGM2GSK3A | |
| SCHEMBL16113892 | 1.00 | AHCY (0.64) | AHCYNT5EHINT1TGM2GSK3A | |
| SCHEMBL17469466 | 1.00 | AHCY (0.64) | AHCYNT5EHINT1TGM2GSK3A | |
| SCHEMBL17198347 | 0.89 | NT5E (0.55) | AHCYNT5EHINT1TGM2GSK3A | |
| SCHEMBL16787413 | 0.88 | AHCY (0.59) | AHCYNT5EHINT1TGM2HPGD | |
| SCHEMBL26622869 | 0.88 | HINT1 (0.56) | AHCYNT5EHINT1TGM2GSK3A | |
| SCHEMBL19130245 | 0.88 | HINT1 (0.56) | AHCYNT5EHINT1TGM2GSK3A | |
| Guanosine SCHEMBL17441728 | 0.87 | HPGD (0.70) | NT5EHINT1TGM2GSK3ARPS6KA3 | |
| SCHEMBL25775138 | 0.86 | NT5E (0.53) | AHCYNT5EHINT1TGM2GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4159741-A1 | METHOD FOR PRODUCING A CHIMERIC POLYNUCLEOTIDE ENCODING A POLYPEPTIDE HAVING A TRIAZOLE-CONTAINING INTERNUCLEOTIDE LINKAGE | ModernaTX, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| EP-3169693-B1 | CHIMERIC POLYNUCLEOTIDES | MODERNATX INC (US) | 2022-03-09 | — | — | EP | disclosed |
| US-10407683-B2 | Circular polynucleotides | MODERNATX, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-20170204152-A1 | CHIMERIC POLYNUCLEOTIDES | MODERNA THERAPEUTICS, INC. (US) | 2017-07-20 | — | — | US | disclosed |
| EP-3169693-A1 | CHIMERIC POLYNUCLEOTIDES | Moderna Therapeutics, Inc. (US) | 2017-05-24 | — | — | EP | disclosed |
| WO-2016011226-A1 | CHIMERIC POLYNUCLEOTIDES | MODERNA THERAPEUTICS, INC. (US) | 2016-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170204152-A1 | CHIMERIC POLYNUCLEOTIDES | NSUN3, TRDMT1, NSUN2 | AHCY 3481/4885NT5E 295/4885HINT1 3560/4885 |
| US-10407683-B2 | Circular polynucleotides | POLN, POLRMT, POLI | AHCY 4233/4885NT5E 139/4885HINT1 3689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.